Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study
- 1 March 1991
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 63 (3) , 420-423
- https://doi.org/10.1038/bjc.1991.97
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- PAMIDRONATE TO REDUCE BONE PAIN IN NORMOCALCAEMIC PATIENT WITH DISSEMINATED PROSTATIC CARCINOMAThe Lancet, 1989
- Bisphosphonates and bone metastasesBritish Journal of Cancer, 1988
- Management of pain and other symptoms of advanced prostatic cancer.1988
- Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.BMJ, 1988
- REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENTThe Lancet, 1987
- Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.1987
- Generalised Increase in Bone Resorption in Carcinoma of the ProstateBritish Journal of Urology, 1985
- COMPARISON OF INTRAVENOUS (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE AND VOLUME REPLETION IN TUMOUR-INDUCED HYPERCALCAEMIAThe Lancet, 1983
- Mechanisms of bone destruction in the development of skeletal metastasesNature, 1976
- Metastases in carcinoma.Analysis of 1000 autopsied casesCancer, 1950